background: This study was designed to establish appropriate body mass index (BMI) level for PCOS women and to compare metabolic abnormalities between PCOS women and control women in Southern China.
Introduction
Approximately 50% of PCOS women are overweight or obese and most of them have the abdominal phenotype. Obesity may play a pathogenic role in the development of the syndrome in susceptible individuals. Obesity, particularly the abdominal phenotype, may be partly responsible for insulin resistance and associated hyperinsulinemia (HIN) in women with PCOS (Broekmans et al., 2006; Lo et al., 2006; Norman et al., 2007) .
The most common measure of excess body weight is the body mass index (BMI), defined as weight in kilograms divided by the square of height in meters. Conventional BMI classifications are overweight (25.0 kg/m 2 BMI , 30.0 kg/m 2 ) and obese (BMI 30.0 kg/m 2 ) (Lo et al., 2006) . These cut-off points were derived primarily in European populations to correspond to risk thresholds for a wide range of chronic diseases and mortality (World Health Organization, 1998) . Emerging evidence suggests that South Asians (people who originate from the Indian subcontinent) and Chinese suffer from an elevated risk of type 2 diabetes, hypertension and dyslipidemia even if their BMI is low, i.e. ,25.0 kg/m 2 (Unwin et al., 1997; Forouhi et al., 1999; Lear et al., 2003; Lovegrove et al., 2003; Jafar et al., 2006) . There is increasing evidence that the associations between BMI, percentage of body fat and body fat distribution differ across populations. Particularly in some Asian populations, normal BMI levels reflect a higher percentage of body fat than that in white or European populations (Chowdhury et al., 1996; Forouhi et al., 1999; Chang et al., 2003) . However, there has been an ongoing debate as to whether these ranges for determining public health and clinical action are appropriate for non-European populations. Furthermore, the ethnic background of women with PCOS may affect the clinical, hormonal and metabolic characteristics. The reported prevalence of obesity in Asian PCOS women varies across countries; several reports have demonstrated a varying prevalence of obesity in PCOS patients in different Asian countries, even in different regions of China (Al-Azemi et al., 2004; Lam et al., 2005; Haq et al., 2007; Kurioka et al., 2007; Li et al., 2007; Shi et al., 2007) .
The aims of the present analysis were to establish appropriate BMI 'trigger points' for clinical action or for representing increased risk of metabolic abnormalities in PCOS women in Southern China. These values should increase the diagnostic power for identifying 'at risk' groups, so that suitable treatments can be implemented at an earlier stage.
Materials and Methods

Subjects
We studied 142 adolescent PCOS women and 857 adult PCOS women, recruited from the gynecological outpatient department of Memorial Group, 2004) . The diagnosis of PCOS was made by the presence of two of the following three criteria: (i) oligomenorrhea and/or anovulation (eight or fewer menstrual cycles in a year or menstrual cycles more than 35 days in length); (ii) clinical and/or biochemical signs of hyperandrogenism; (iii) polycystic ovaries (presence of 12 or more follicles in each ovary measuring 2 -9 mm in diameter and/or increased ovarian volume .10 ml) and exclusion of other etiologies (e.g. congenital adrenal hyperplasia, androgen-secreting tumors and Cushing's syndrome). Any medications known to affect sex hormone or carbohydrate metabolism were discontinued for at least a month before the study (except oral contraceptives, which were stopped 3 months before study entry). All subjects did not use any hypolipidemic or blood pressure (BP)-lowering drugs. All women were in good health.
BMI There were also 922 controls (742 adults and 180 adolescents) enrolled in this study over the same period. They visited the health-care center in our hospital as a part of group checkup for work or an association or an individual need for an annual comprehensive medical checkup with no specific health problems. Subjects ranged in age from 16 to 45 years old and did not show hirsutism, acne or male-type alopecia. All of them had absolutely regular menstrual cycle periods between 21 and 35 days, and none of them satisfied any of the PCOS criteria of the 2003 Rotterdam consensus. All control subjects received an ultrasonographic examination by one gynecologist, specialized in reproductive endocrinology. Women who had any pathologic findings or polycystic ovaries in their pelvic area were excluded from the present study. Women who had any medication that may affect on endocrinological or metabolic changes were also excluded.
Clinical and biochemical measurements
Clinical variables such as the WC, hip circumference, body weight and height were assessed in all subjects. BMI was calculated as weight (kg) divided by the square of height (m 2 ). Whole blood was sampled on day 1 -5 of the menstrual cycle or during the period of amenorrhea in PCOS patients. Basal gonadotrophin hormone levels were measured in all PCOS subjects, including serum LH and FSH. Women with PCOS and control subjects were evaluated for serum total testosterone (TT), free testosterone (FT) using RIA (Simens, Los Angeles, CA, USA) and fasting plasma insulin levels (FI) using a commercial kit (BioSource Europe SA, Belgium). Fasting plasma glucose (FG) was measured using commercial kits (BioSource Europe SA). Serum TG and HDL were measured using a 200FR system (Toshiba, Tokyo, Japan).
Statistical analysis
We assessed the normality of the distribution of all continuous variables using the Kolmogorov-Smirnov test. Because the data were not normally distributed, continuous variables were presented as median values with an inter-quartile range (25-75th percentile), and differences in medians between the groups were determined by the Mann-Whitney test. Partial correlations were used to compare the correlation between metabolic disorders and BMI. Pearson x 2 test was used to analyze the differences between the groups and to obtain an odds ratio (OR). Receiver-operating characteristic (ROC) curves were generated, and confidence intervals (CIs) for areas under ROC curves, sensitivity, specificity and significance of differences between ROC curves were calculated using the non-parametric method.
Youden index (sensitivity þ specificity-1) was calculated to determine the best compromise between sensitivity and specificity. When the value was closer to 1, it was indicating the greater diagnostic value.
All data were analyzed using Statistical Package for the Social Sciences for Windows version 13.0 (SPSS Inc., Chicago, IL, USA). A P-value of ,0.05 was considered significant.
Results
Basic hormonal and metabolic features of all women studied
As shown in Table I , the mean age at menarche and BMI of PCOS women were both significantly higher than that of the control group (P , 0.001). The systolic BP (SBP), diastolic BP (DBP) and levels of LH, TT, FG, FI and TG in the PCOS group were all significantly higher than those in the control group (P , 0.05). There were no significant differences in age or levels of FSH or FT between the two groups.
Basic hormonal and metabolic features of adult and adolescent subgroups
As shown in Table II , BMI levels were higher in the adult group compared with the adolescent group, only in the control group. There were no significant differences in waist and hip measurements between the PCOS adult group and the PCOS adolescent group, but there was significant difference in W/H between these two groups. Compared with the PCOS adolescent group and the control adult group, the PCOS adult group had significantly higher SBP and DBP readings. Higher SBP and DBP readings were also found in the PCOS adolescent group compared with the control adolescent group.
As also shown in Table II , FSH levels were higher in both adult groups compared with the adolescent groups. Levels of LH and TT were higher in the PCOS groups than in the control groups, regardless of whether they were adults and adolescents. FG levels were also higher in the PCOS groups than in control groups. Higher TG levels were observed in the PCOS adult group than in either the PCOS adolescent or the adult control groups. For both adults and adolescents, the PCOS groups had higher FI levels compared with the Appropriate BMI levels for PCOS patients control groups. There was no significant difference in HDL between the PCOS adult and adolescent groups.
Percentiles of fasting insulin levels and BMI in controls
The 95th percentiles of BMI were 23.67 and 25.46 kg/m 2 in adolescent and adult controls, respectively. HIN was defined as fasting insulin above the 95th percentile (11.87 mU/l) in controls.
Distribution of BMI in PCOS patients and controls
Figures 1 and 2 show the distribution of BMI in PCOS patients and age-matched controls. There were 133 (15.52%) adults with PCOS who had a BMI higher than the 95th centile compared with 4.65% of control adults. There were 50 (35.21%) adolescents with PCOS who had a higher BMI above the 95th centile compared with 5.13% of control adolescents. The proportion of all PCOS patients with a BMI above 23 kg/m 2 was 34.63%.
Prevalence of metabolic disorders in different BMI subgroups
We classified the women with PCOS into four BMI groups and the prevalence of metabolic disorders increased with each BMI group (Table III) . The risks of presenting HIN or dyslipidemia in PCOS patients were 2-to 8-fold higher than in the controls in all four BMI groups. In Group 1, only 4-6% of PCOS patients had HIN or dyslipidemia while nearly 50% of PCOS patients with HIN and 30% of PCOS patients with dyslipidemia belonged to Group 3 or 4.
Correlation between BMI and insulin, lipids and central obesity in PCOS patients
Serum insulin levels correlated positively with BMI (r ¼ 0.587; P , 0.001). BMI correlated positively with TG (r ¼ 0.421; P , 0.001), but negatively with HDL-C (r ¼ 20.502; P , 0.001). Both waist (r ¼ 0.865; P , 0.001) and W/H (r ¼ 0.636; P , 0.001) measurements correlated positively with BMI.
Youden index and AUCs for detecting MS in PCOS women
When the BMI threshold was 23 kg/m 2 , the compromise of sensitivity and specificity was better than at other BMI thresholds for detecting MS. The diagnostic value of BMI was greater than that of HIN or of dyslipidemia (Fig. 3 , Table IV ).
Prevalence of MS in PCOS patients
The prevalence of MS in PCOS patients was 18.9% based on the ATP III criteria of MS. As shown in Table V , the prevalence of MS increased with each increment of BMI. The prevalence of MS in PCOS patients was particularly increased when the BMI was above 23 kg/m 2 .
Discussion
BMI is an acceptable proxy for thinness and fatness, and has been directly related to health risks and death rates in many populations. However, studies have shown that BMI differs across ethnic groups (Dudeja et al., 2001) . Wang et al. (1994) showed that Chinese people originating from the Shanghai region and living in New York City had a lower BMI but a higher percentage of body fat than white people of the same age and sex. Studies in Asian populations have shown that the relationship between body fat percentage (BF%) and BMI is different between Asian and Caucasians, and among the different ethnic populations in Asia as well. A specific BMI may reflect a higher percentage of body fat in an Asian population compared with the same BMI in white or European populations (Rush et al., 2004 In the present study, the proportion with a BMI above 23 kg/m 2 in PCOS patients was 34.63% (346/999), whereas the proportion with a BMI above 25 kg/m 2 (conventional criteria for overweight) in the same group was 20.92% (209/999). The prevalence of metabolic disorders increased with BMI in the present study. The risk of presenting HIN and dyslipidemia was higher in PCOS patients than in controls, even in lean subgroups. And for adult and adolescent subgroups, BP, LH, TT, FG, FI and TG were higher in PCOS patients than in controls. The prevalence of metabolic disorders increased significantly when the BMI was above 23 kg/m 2 . In our previous study of 915 unselected Chinese women, 7.5% of patients were overweight (BMI 24.0 -27.9 kg/m 2 ), and 1.3% were obese (BMI 28 kg/m 2 ) (Chen et al., 2008) . This may have demonstrated a valuable BMI threshold in reproductive age women in Southern China. In the same study, we found that the prevalence of overweight women among those with PCOS was 20%, which was lower than that in PCOS women in USA (i.e. 24%) and Spain (i.e. 30%) (Asuncion et al., 2000; Azziz et al., 2004) . However, the prevalence of overweight women in that PCOS sample was similar to that observed in Japanese PCOS patients (i.e. 20%) (The Committee for Reproductive Endocrine in Japan Society of Obstetrics Gynecology, 1993) . These data also suggested that Asian PCOS patients had lower BMI compared with European patients. Our present data further suggested that 'normal ranges' for obesity using BMI levels derived in European populations may be misleading when applied to other populations such as South Asians and Chinese (Chowdhury et al., 1996; Unwin et al., 1997; Forouhi et al., 1999; Chang et al., 2003; Lear et al., 2003; Lovegrove et al., 2003; Jafar et al., 2006) .
The pathway linking obesity to clinical events is mediated partially through its strong association with the development of diabetes, hypertension and dyslipidemia (World Health Organization, 1998). Therefore, our study tried to find the appropriate BMI level for PCOS women in Southern China by analyzing the above important risk factors of obesity. Our findings showed that serum insulin, TG, waist and W/H were all correlated positively with BMI in PCOS women. As the BMI increased, the prevalence of HIN, dyslipidemia and central obesity also increased in PCOS patients.
In this study, the prevalence of MS in Chinese PCOS patients was 18.9%. Levels of BP, FG, FI and TG in PCOS women were higher than in controls, even when divided into adult and adolescent subgroups. This suggests that the risks of having metabolic disorders are significantly higher in PCOS patients compared with controls. The prevalence of MS in PCOS patients also increased particularly when BMI was above 23 kg/m 2 . These findings have important implications for clinicians, who needed to be aware that the definition of a 'normal' or average BMI may not be useful when applying it to non-European ethnic groups.
Various studies have contributed to defining the appropriate BMI level. Previous studies had clearly shown that the receiver-operating For each screening test, sensitivity is plotted against 100-specificity. The ideal test would have 100% sensitivity and 100% specificity and reach the upper left corner of the graph; a test with no predictive value would lie along the diagonal between the lower left corner and the upper right corner. These curves facilitate assessment of the sensitivity (Sens) and specificity (Spec) of every value obtained from the screening tests. For each test, examples of data points with associated Sens and Spec are displayed to illustrate the characteristics of the test; these data points are not proposed as thresholds between normal and abnormal results.
curve characteristic approach was dependent on the BMI distribution (Dudeja et al., 2001; Stevens et al., 2002) . In general, a more rightward distribution would produce a higher optimal BMI level by using the receiver-operating curve characteristic method (Asuncion et al., 2000) . Using the ROC and Youden index, our findings showed that the sensitivity and specificity for evaluating metabolic disorders were optimal at the point of BMI 23 kg/m 2 .
Some patients with PCOS may have a higher risk of metabolic disorders despite lower BMI. For these patients, metabolic disturbances need to be checked as early as possible and so they can proceed to treatment earlier. According to the above results, PCOS patients with a BMI above 23 kg/m 2 should be alerted for clinical action.
However, such a change would require public health policies and clinical management guidelines, and could lead to increased cost for governments (i.e. more treatment at lower thresholds).
Study limitations
Because of the cross-sectional design and modest sample size of the present study, we could not be certain whether these markers showed ethnic variation in their relation to clinical events such as MS. This would require a much larger prospective study involving several thousand metabolic disorders in each of several ethnic groups. WC measurements and HDL-C level were unavailable in the controls; therefore, the prevalence of MS in women with PCOS could not be compared with that in controls from the same region. We look forward to evaluating this issue in a future paper.
Conclusion
The prevalence of obesity in Asian PCOS patients is different from that reported by European populations. Thus, suitable recommendations for appropriate BMI levels in Asian PCOS populations and population-specific BMI levels are essential. In our study, a BMI above 23 kg/m 2 reflected an increasing diagnostic power for metabolic disorders in PCOS patients in Southern China.
In the development of long-term risk with PCOS, obesity was one of the important pathogenesis, which may substantially contribute to determine the health state in patients. It is important to take into consideration the ethnic background of patients related to PCOS. Above all, it is essential to suggest the age and race match BMI level to define overweight and obesity in PCOS patients. If we identify 'at risk' groups in overweight PCOS patients, and suitable treatments can be implemented at an earlier stage, we could play a role as a 'gate-keeper'.
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